Iovance Biotherapeutics, Inc. (IOVA)
8.07
-0.22
(-2.65%)
USD |
NASDAQ |
Aug 24, 16:00
8.05
-0.02
(-0.25%)
After-Hours: 20:00
Iovance Biotherapeutics Shareholders Equity (Quarterly) : 736.04M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 736.04M |
| March 31, 2026 | 721.75M |
| December 31, 2025 | 698.58M |
| September 30, 2025 | 702.29M |
| June 30, 2025 | 698.49M |
| March 31, 2025 | 767.86M |
| December 31, 2024 | 710.40M |
| September 30, 2024 | 773.46M |
| June 30, 2024 | 768.54M |
| March 31, 2024 | 680.02M |
| December 31, 2023 | 584.61M |
| September 30, 2023 | 674.01M |
| June 30, 2023 | 578.57M |
| March 31, 2023 | 666.88M |
| December 31, 2022 | 499.64M |
| September 30, 2022 | 393.74M |
| June 30, 2022 | 472.69M |
| March 31, 2022 | 551.99M |
| December 31, 2021 | 621.66M |
| September 30, 2021 | 698.33M |
| June 30, 2021 | 744.41M |
| March 31, 2021 | 647.43M |
| December 31, 2020 | 656.50M |
| September 30, 2020 | 711.84M |
| June 30, 2020 | 758.31M |
| Date | Value |
|---|---|
| March 31, 2020 | 243.31M |
| December 31, 2019 | 298.97M |
| September 30, 2019 | 355.06M |
| June 30, 2019 | 397.42M |
| March 31, 2019 | 434.93M |
| December 31, 2018 | 466.19M |
| September 30, 2018 | 254.16M |
| June 30, 2018 | 270.57M |
| March 31, 2018 | 292.56M |
| December 31, 2017 | 145.48M |
| September 30, 2017 | 165.44M |
| June 30, 2017 | 129.15M |
| March 31, 2017 | 149.89M |
| December 31, 2016 | 166.92M |
| September 30, 2016 | 179.13M |
| June 30, 2016 | 188.94M |
| March 31, 2016 | 98.94M |
| December 31, 2015 | 104.02M |
| September 30, 2015 | 109.37M |
| June 30, 2015 | 112.87M |
| March 31, 2015 | 111.63M |
| December 31, 2014 | 44.85M |
| September 30, 2014 | 16.16M |
| June 30, 2014 | 17.38M |
| March 31, 2014 | 16.81M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Agenus, Inc. | -199.08M |
| Amgen, Inc. | 11.69B |
| Neurocrine Biosciences, Inc. | 3.694B |
| Anika Therapeutics, Inc. | 137.28M |
| BioCryst Pharmaceuticals, Inc. | -454.29M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 915.53M |
| Total Liabilities (Quarterly) | 179.49M |
| Debt to Equity Ratio | 0.0625 |
| Current Ratio | 4.345 |
| Net Debt Paydown Yield | 0.08% |